Risk factors for monoclonal gammopathy of undetermined significance: a systematic review

被引:21
作者
Castaneda-Avila, Maira A. [1 ]
Ulbricht, Christine M. [1 ]
Epstein, Mara Meyer [1 ,2 ,3 ]
机构
[1] Univ Massachusetts, Sch Med, Dept Populat & Quantitat Hlth Sci, Worcester, MA USA
[2] Univ Massachusetts, Sch Med, Meyers Primary Care Inst, 365 Plantat St,Suite 100, Worcester, MA 01605 USA
[3] Univ Massachusetts, Sch Med, Dept Med, 365 Plantat St,Suite 100, Worcester, MA 01605 USA
基金
美国国家卫生研究院;
关键词
MGUS; Risk factors; Systematic review; PRECEDES MULTIPLE-MYELOMA; SIGNIFICANCE MGUS; PRIOR AUTOIMMUNE; POOLED ANALYSIS; PREVALENCE; OBESITY; MORTALITY; CANCER; WHITE; METAANALYSIS;
D O I
10.1007/s00277-021-04400-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Monoclonal gammopathy of undetermined significance (MGUS), precursor of multiple myeloma, is an asymptomatic plasma cell disorder that overproduces serum monoclonal protein. Older age, male sex, black race, and family history of MGUS increase the risk of MGUS, yet other risk factors are known. We systematically reviewed observational epidemiological studies that examined sociodemographic, clinical, and behavioral risk factors for the development of MGUS. The protocol for this study was registered on the PROSPERO registry for systematic reviews. We identified epidemiological studies from PubMed and Scopus. Articles were limited to those written in English and published before February 2019. Five case-control and three cohort studies were eligible for data extraction. Studies evaluating factors associated with MGUS risk are limited, with conflicting conclusions regarding risk associated with obesity. Despite the limited research, a significant elevated risk for being diagnosed with MGUS was associated with several specific prior infections, inflammatory disorders, and smoking. The sparse existing literature suggests an increased risk of MGUS associated with several risk factors related to immune function. Further research is needed to explore the potential mechanisms underlying the development of MGUS and to confirm risk factors, both modifiable and non-modifiable.
引用
收藏
页码:855 / 863
页数:9
相关论文
共 50 条
  • [21] Monoclonal gammopathy of undetermined significance: prognostic factor and risk of progression
    Emilce Alejandre, Mariel
    Sackmann, Federico
    Pavlovsky, Santiago
    Remaggi, Guillermina
    Arturo Pavlovsky, Miguel
    Pandolfo, Marcela
    Madalena, Leticia
    Fraind, Susana
    Laura Facio, Maria
    Pavlovsky, Astrid
    Bresciani, Pablo
    Pizzolato, Marco
    ACTA BIOQUIMICA CLINICA LATINOAMERICANA, 2013, 47 (01): : 71 - 84
  • [22] Monoclonal gammopathy of undetermined significance
    Anguille, Sebastien
    Bryant, Christian
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2013, 185 (15) : 1345 - 1345
  • [23] Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance
    Baldursdottir, Theodora Run
    Love, Thorvardur Jon
    Gislason, Gauti Kjartan
    Bjorkholm, Magnus
    Mellqvist, Ulf-Henrik
    Lund, Sigrun Helga
    Blimark, Cecilie Hveding
    Turesson, Ingemar
    Hultcrantz, Malin
    Landgren, Ola
    Kristinsson, Sigurdur Yngvi
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 106 (03) : 380 - 388
  • [24] Monoclonal gammopathy of undetermined significance
    Zandecki, M
    Geneviève, F
    Jego, P
    Grosbois, B
    REVUE DE MEDECINE INTERNE, 2000, 21 (12): : 1060 - 1074
  • [25] Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women
    Landgren, Ola
    Rajkumar, S. Vincent
    Pfeiffer, Ruth M.
    Kyle, Robert A.
    Katzmann, Jerry A.
    Dispenzieri, Angela
    Cai, Qiuyin
    Goldin, Lynn R.
    Caporaso, Neil E.
    Fraumeni, Joseph F.
    Blot, William J.
    Signorello, Lisa B.
    BLOOD, 2010, 116 (07) : 1056 - 1059
  • [26] Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance
    Vachon, Celine M.
    Kyle, Robert A.
    Therneau, Terry M.
    Foreman, Barbara J.
    Larson, Dirk R.
    Colby, Colin L.
    Phelps, Tara K.
    Dispenzieri, Angela
    Kumar, Shaji K.
    Katzmann, Jerry A.
    Rajkumar, S. Vincent
    BLOOD, 2009, 114 (04) : 785 - 790
  • [27] The Undetermined Significance of Screening for Monoclonal Gammopathy of Undetermined Significance
    Qunaj, Lindor
    Lentzsch, Suzanne
    Neugut, Alfred I.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (12) : 1547 - 1549
  • [28] Monoclonal gammopathy of undetermined significance
    Mouhieddine, Tarek H.
    Weeks, Lachelle D.
    Ghobrial, Irene M.
    BLOOD, 2019, 133 (23) : 2484 - 2494
  • [29] Evaluation of Sarcopenia in Patients with Monoclonal Gammopathy of Undetermined Significance
    Kul, Ayse Nilgun
    Tuna, Mujgan Kaya
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (12)
  • [30] The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance
    Gregersen, H
    Madsen, KM
    Sorensen, HT
    Schonheyder, HC
    Ibsen, JS
    Dahlerup, JF
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1998, 61 (02) : 140 - 144